US Edition
Published • loading... • Updated
A New Lyme Disease Vaccine Could Soon Be Available for Humans
The vaccine was well tolerated and showed more than 70% efficacy in people ages 5 and older, with no safety concerns identified.
- Pfizer and Valneva shared last week that their vaccine VALOR, short for "Vaccine Against Lyme for Outdoor Recreationists," demonstrated more than 70% efficacy in preventing Lyme disease in individuals ages five and older.
- Lyme disease is a bacterial infection spread by blacklegged ticks, causing fever, fatigue, and characteristic rashes; the CDC estimates as many as 476,000 people are diagnosed and treated annually in the U.S.
- The drugmaker reported the vaccine was well tolerated with no safety concerns identified at the time of analysis, while most cases of Lyme disease are currently treated successfully with antibiotics.
- No vaccines to prevent Lyme disease are currently available for humans, though regulatory approval from the Food and Drug Administration could change that if granted to the companies.
- Lyme disease is most common in the Northeast and named after Lyme, Connecticut, where it was first discovered in 1975, though a previous vaccine approved in 1998 was pulled from the market in 2002.
Insights by Ground AI
12 Articles
12 Articles
Pfizer says long-awaited Lyme vaccine was effective in study
Pfizer Inc. said its experimental Lyme disease vaccine was 73% effective against the tick-borne illness, though fewer-than-expected cases in a study made it hard to determine how well it works on a large scale.
·New Hampshire, United States
Read Full Article
Coverage Details
Total News Sources12
Leaning Left1Leaning Right0Center11Last UpdatedBias Distribution92% Center
Bias Distribution
- 92% of the sources are Center
92% Center
C 92%
Factuality
To view factuality data please Upgrade to Premium
